Vanguard Group Inc. Reduces Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Vanguard Group Inc. lessened its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.3% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,000,689 shares of the medical equipment provider’s stock after selling 242,573 shares during the quarter. Vanguard Group Inc. owned approximately 10.22% of Lantheus worth $683,267,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Intrust Bank NA lifted its stake in Lantheus by 2.9% in the first quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider’s stock worth $431,000 after acquiring an additional 125 shares during the period. Westfield Capital Management Co. LP lifted its stake in Lantheus by 2.2% in the first quarter. Westfield Capital Management Co. LP now owns 1,589,145 shares of the medical equipment provider’s stock worth $155,101,000 after acquiring an additional 34,052 shares during the period. Allianz SE lifted its stake in Lantheus by 103.4% in the first quarter. Allianz SE now owns 7,906 shares of the medical equipment provider’s stock worth $772,000 after acquiring an additional 4,020 shares during the period. Banco Santander S.A. purchased a new stake in Lantheus in the first quarter worth $237,000. Finally, Klein Pavlis & Peasley Financial Inc. purchased a new stake in Lantheus in the first quarter worth $222,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Buying and Selling at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of the firm’s stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the transaction, the director directly owned 318,650 shares in the company, valued at $24,481,879.50. This trade represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.50% of the stock is owned by insiders.

Lantheus Stock Performance

Shares of Lantheus stock opened at $53.79 on Thursday. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $3.66 billion, a P/E ratio of 14.31 and a beta of 0.14. The business has a fifty day simple moving average of $74.90 and a two-hundred day simple moving average of $86.04. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $118.21.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.08). Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The company had revenue of $378.05 million for the quarter, compared to the consensus estimate of $389.69 million. During the same quarter in the previous year, the business earned $1.80 earnings per share. Lantheus’s revenue was down 4.1% compared to the same quarter last year. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LNTH has been the subject of a number of research analyst reports. Truist Financial set a $63.00 price target on Lantheus and gave the stock a “hold” rating in a research note on Monday. JMP Securities lowered their price objective on Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a research report on Thursday, August 7th. William Blair reissued a “market perform” rating on shares of Lantheus in a research report on Wednesday, July 16th. B. Riley lowered their price objective on Lantheus from $122.00 to $109.00 and set a “buy” rating for the company in a research report on Monday, June 23rd. Finally, Mizuho lowered their price objective on Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, August 7th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $105.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.